A
16.41
-0.20 (-1.20%)
| Penutupan Terdahulu | 16.61 |
| Buka | 16.34 |
| Jumlah Dagangan | 166,954 |
| Purata Dagangan (3B) | 399,145 |
| Modal Pasaran | 509,798,560 |
| Harga / Buku (P/B) | 4.63 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| EPS Cair (TTM) | -2.30 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 19.01% |
| Nisbah Semasa (MRQ) | 22.53 |
| Aliran Tunai Operasi (OCF TTM) | -53.00 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -39.36 M |
| Pulangan Atas Aset (ROA TTM) | -22.88% |
| Pulangan Atas Ekuiti (ROE TTM) | -38.04% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Alto Neuroscience, Inc. | Menaik | Menaik |
AISkor Stockmoo
-0.6
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.0 |
| Purata | -0.63 |
|
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 7.48% |
| % Dimiliki oleh Institusi | 77.52% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Alpha Wave Global, Lp | 30 Sep 2025 | 3,707,757 |
| Armistice Capital, Llc | 30 Sep 2025 | 1,636,000 |
| Vestal Point Capital, Lp | 30 Sep 2025 | 950,000 |
| 72 Investment Holdings, Llc | 30 Sep 2025 | 667,778 |
| Alkeon Capital Management Llc | 30 Sep 2025 | 477,101 |
| Integral Health Asset Management, Llc | 30 Sep 2025 | 400,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 30.00 (Chardan Capital, 82.82%) | Beli |
| Median | 26.00 (58.44%) | |
| Rendah | 22.00 (Baird, 34.07%) | Beli |
| Purata | 26.00 (58.44%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 13.97 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 05 Jan 2026 | 30.00 (82.82%) | Beli | 16.53 |
| BTIG | 17 Nov 2025 | 27.00 (64.53%) | Beli | 13.80 |
| Baird | 13 Nov 2025 | 22.00 (34.06%) | Beli | 11.35 |
| Jefferies | 12 Nov 2025 | 25.00 (52.35%) | Beli | 14.20 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 14 Jan 2026 | Pengumuman | Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression |
| 13 Jan 2026 | Pengumuman | Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology |
| 03 Dec 2025 | Pengumuman | Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 |
| 12 Nov 2025 | Pengumuman | Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights |
| 28 Oct 2025 | Pengumuman | Alto Neuroscience to Participate in Upcoming Investor Conferences |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |